Related Experiment Video
Updated: May 29, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.6K
Summary
New once-weekly insulin formulations offer improved convenience for diabetes management. This review critically appraises their development, mechanisms, and clinical study outcomes.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Mellitus Research
Background:
- Insulin therapy remains central to diabetes management.
- Continuous innovation in insulin formulations aims to improve patient adherence and glycemic control.
- The centenary of commercial insulin highlights ongoing advancements in its delivery and efficacy.
Purpose of the Study:
- To review the mechanisms behind novel long-acting insulin formulations.
- To critically appraise the early clinical research and registration study results of once-weekly insulins.
- To provide an overview of the latest developments in insulin therapy.
Main Methods:
- Narrative review of published literature.
- Analysis of data from clinical registration studies.
- Critical appraisal of pharmacokinetic and pharmacodynamic properties.
Main Results:
- A first-generation once-weekly insulin is now available in several markets.
- Emerging data from registration studies of a second once-weekly insulin are being reported.
- These new formulations demonstrate prolonged duration of action through specific technological advancements.
Conclusions:
- Once-weekly insulin formulations represent a significant advancement in diabetes care.
- Further research and real-world data are crucial for understanding the long-term impact and patient benefits.
- These innovations hold promise for enhancing treatment convenience and potentially improving patient outcomes.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
162
01:16Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
01:06Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
01:25Insulin: Biosynthesis, Chemistry, and Preparation
346
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
346
01:17Oral Hypoglycemic Agents: Sulfonylureas
184
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
184
01:24Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292